Live Breaking News & Updates on R Metastatic Breast Cancer

The European Commission has approved elacestrant for the treatment of postmenopausal women and men with estrogen receptor–positive, HER2-negative, locally advanced, or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least 1 line of endocrine therapy including a CDK4/6 inhibitor. ....

San Antonio , United States , Elcin Barker Ergun , Giuseppe Curigliano , European Institute Of Oncology , Division Of Early Drug Development , European Commission , Menarini Group , University Of Milano , Barker Ergun , Antonio Breast Cancer Symposium , Early Drug Development , European Institute , Estrogen Receptor Positive , Her2 Negative , Locally Advanced , R Metastatic Breast Cancer , Emerald Trial ,